Preferred Label : WT1-targeted IL-2-based Fusion Protein CUE-102;
NCIt synonyms : Immuno-STAT CUE-102; Selective Targeting and Alteration of T-cells CUE-102; Fusion Protein CUE-102; IL-2-based CUE-102;
NCIt definition : A Fc-engineered fusion protein composed of two human leukocyte antigen (HLA) molecules
presenting a Wilms' tumor 1 (WT1) peptide that are each linked to two affinity-attenuated
interleukin 2 (IL-2; IL2) molecules, with potential immunomodulating and antineoplastic
activities. The HLA molecules presenting a WT1 peptide are peptide-HLA-A*0201 major
histocompatibility complex (pMHC) derived from the WT1 peptide encoded by the amino
acids 37-45. Upon administration of CUE-102, the pMHC moiety selectively targets,
binds to and activates the T cell receptor (TCR) on WT1-specific T-lymphocytes. By
selectively delivering the IL-2 moiety to the CD8-positive T-cells, the IL-2 moiety
specifically binds to IL-2 receptors on tumor-specific effector T-cells and mediates
the selective expansion of WT1-specific T-cells. This increases the T-cell-mediated
anti-tumor immune response against WT1-expressing tumor cells and thereby eliminates
tumor cells. The simultaneous engagement of co-regulatory molecules and pMHC binding
mimics the signals delivered by antigen presenting cells (APCs) to T-cells during
a natural immune response. WT1, a co-fetal protein and tumor-associated antigen (TAA),
is overexpressed in a number of cancers. The IL-2 variant ('not-alpha' IL-2) preferentially
activates tumor-specific CD8 T-cells and does not prefer to bind to the IL-2 receptor
alpha subunit; this minimizes systemic effects on non-tumor-specific T-cells. This
minimizes induction of pro-inflammatory cytokines release and non-specific and systemic
activation of immune cells.;
Molecule name : CUE 102; CUE-102;
NCI Metathesaurus CUI : CL1792362;
Origin ID : C187689;
UMLS CUI : C5706432;
Semantic type(s)
- concept_is_in_subset
- has_target
